Allogene Therapeutics, Inc. financial data

Symbol
ALLO on Nasdaq
Location
210 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 911 % -27.2%
Debt-to-equity 31 % +23.2%
Return On Equity -58.6 % -8.57%
Return On Assets -44.8 % -3.73%
Operating Margin -1.24M % -260%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 222M shares +6.11%
Common Stock, Shares, Outstanding 220M shares +5.3%
Entity Public Float 354M USD -36.4%
Common Stock, Value, Issued 220K USD +5.26%
Weighted Average Number of Shares Outstanding, Basic 219M shares +15.2%
Weighted Average Number of Shares Outstanding, Diluted 219M shares +15.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 180M USD -11.4%
General and Administrative Expense 61.1M USD -9.61%
Operating Income (Loss) -254M USD +12%
Nonoperating Income (Expense) 17.8M USD +85.2%
Net Income (Loss) Attributable to Parent -237M USD +15.2%
Earnings Per Share, Basic -1 USD/shares +30.8%
Earnings Per Share, Diluted -1 USD/shares +30.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.3M USD -69.3%
Cash, Cash Equivalents, and Short-term Investments 303M USD -31.9%
Assets, Current 283M USD -38.2%
Property, Plant and Equipment, Net 78.9M USD -14.4%
Operating Lease, Right-of-Use Asset 42M USD -28.1%
Other Assets, Noncurrent 3.83M USD -40.6%
Assets 471M USD -27.3%
Accounts Payable, Current 4.85M USD -62.5%
Employee-related Liabilities, Current 12.1M USD -4.1%
Contract with Customer, Liability, Current 86K USD 0%
Liabilities, Current 31.7M USD -15.1%
Operating Lease, Liability, Noncurrent 79.2M USD -8.91%
Other Liabilities, Noncurrent 15.1M USD +100%
Liabilities 126M USD -4.41%
Accumulated Other Comprehensive Income (Loss), Net of Tax -45K USD +94.2%
Retained Earnings (Accumulated Deficit) -1.93B USD -14%
Stockholders' Equity Attributable to Parent 345M USD -33.1%
Liabilities and Equity 471M USD -27.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.9M USD +5.31%
Net Cash Provided by (Used in) Financing Activities 14M USD +748%
Net Cash Provided by (Used in) Investing Activities 6.18M USD -72.1%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 220M shares +5.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.8M USD -2.02%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 62.6M USD -65.4%
Deferred Tax Assets, Valuation Allowance 445M USD +11.3%
Deferred Tax Assets, Gross 456M USD +9.14%
Operating Lease, Liability 87M USD -7.66%
Depreciation 3.56M USD +1.37%
Payments to Acquire Property, Plant, and Equipment 99K USD +1138%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -236M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid 113M USD -10.3%
Property, Plant and Equipment, Gross 146M USD -1.77%
Operating Lease, Liability, Current 7.76M USD +7.41%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.6M USD +3.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.2M USD +1.89%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 25.7M USD -18.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.1M USD +3.42%
Deferred Tax Assets, Operating Loss Carryforwards 244M USD +15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 22M USD +16.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 15.5M USD +9.97%
Operating Lease, Payments 3.1M USD +3.33%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.1M USD -12.8%
Share-based Payment Arrangement, Expense 47.1M USD -15.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%